Overview

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Tegaserod